Want to see AU:ALC full AI Analyst Report?
Top Page
Alcidion Group Limited
(Sydney:ALC)
Select Model
Select Model
Rating:67Neutral
Price Target:
AU$0.10
▲(5.56% Upside)
Action:Reiterated
Date:01/22/26
The score is driven mainly by improving financial performance (strong revenue growth, very low leverage, and sharply better cash generation) and supportive technical trend signals (price above key moving averages with positive MACD). These positives are moderated by an expensive valuation (P/E 108.33) and still-weak operating profitability (negative EBIT margin and low net margin).
Positive Factors
Sustained Revenue Growth
Consistent top-line growth near mid-teens suggests expanding product adoption across hospitals and health services. In a software-led model, steady revenue growth supports longer-term contract momentum, recurring license renewals and cross-sell opportunities that underpin durable cash flows and scaling.
Negative Factors
Negative EBIT Margin
Negative EBIT indicates operating expenses currently exceed operating profits, suggesting the company has yet to achieve consistent operating leverage. Sustained profitability depends on converting revenue growth into operating margins by optimizing SG&A and implementation cost structures.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained Revenue Growth
Consistent top-line growth near mid-teens suggests expanding product adoption across hospitals and health services. In a software-led model, steady revenue growth supports longer-term contract momentum, recurring license renewals and cross-sell opportunities that underpin durable cash flows and scaling.
Read all positive factors
Alcidion Group Limited (ALC) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$120.92M
Dividend YieldN/A
Average Volume (3M)796.98K
Price to Earnings (P/E)31.4
Beta (1Y)1.00
Revenue Growth36.43%
EPS GrowthN/A
CountryAU
Employees136
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)<0.01
Shares Outstanding1,343,558,700
10 Day Avg. Volume536,053
30 Day Avg. Volume796,979
Financial Highlights & Ratios
PEG Ratio-0.70
Price to Book (P/B)1.57
Price to Sales (P/S)3.38
P/FCF Ratio24.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.14Price Target Upside58.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)<0.01
Revenue Forecast (FY)AU$53.97M
Alcidion Group Limited Business Overview & Revenue Model
Company Description
Alcidion Group Limited operates as a healthcare technology firm, specializing in the creation and licensing of software products across Australia, New Zealand, and the United Kingdom. Its flagship product, Miya Precision, is a consolidated platfor...
How the Company Makes Money
Alcidion makes money primarily by selling and supporting its healthcare software to hospital and healthcare customers. Key revenue streams include: (1) recurring software revenue from licensing/subscriptions and ongoing support/maintenance for its...
Alcidion Group Limited Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
72
Positive
Cash Flow
78
Positive
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 48.62M | 40.79M | 37.06M | 40.40M | 34.35M | 25.88M |
| Gross Profit | 25.73M | 35.99M | 31.92M | 1.25M | 3.29M | 3.52M |
| EBITDA | 7.27M | 1.94M | -4.50M | -1.43M | -1.58M | -474.00K |
| Net Income | 3.87M | 1.65M | -8.42M | -3.62M | -4.41M | -2.24M |
Balance Sheet | ||||||
| Total Assets | 118.08M | 115.63M | 114.46M | 120.68M | 128.35M | 58.38M |
| Cash, Cash Equivalents and Short-Term Investments | 14.20M | 17.70M | 11.80M | 14.64M | 17.34M | 25.03M |
| Total Debt | 1.32M | 1.41M | 1.70M | 2.15M | 2.48M | 181.00K |
| Total Liabilities | 28.45M | 27.82M | 27.52M | 30.52M | 34.40M | 13.16M |
| Stockholders Equity | 89.64M | 87.80M | 86.94M | 90.17M | 93.95M | 45.22M |
Cash Flow | ||||||
| Free Cash Flow | 7.17M | 5.64M | -7.18M | -285.00K | 685.00K | 1.23M |
| Operating Cash Flow | 7.32M | 5.76M | -7.13M | 169.00K | 996.00K | 1.54M |
| Investing Cash Flow | -147.00K | -125.00K | -53.00K | -3.14M | -59.74M | -9.84M |
| Financing Cash Flow | -789.00K | -764.00K | 4.34M | -616.00K | 51.33M | 17.23M |
Alcidion Group Limited Technical Analysis
Negative
0.09
Price Trends
0.10
Negative
0.10
Negative
0.10
Negative
Market Momentum
>-0.01
Negative
12.36
Positive
37.50
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ALC, the sentiment is Negative. The current price of 0.09 is above the 20-day moving average (MA) of 0.09, below the 50-day MA of 0.10, and below the 200-day MA of 0.10, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 12.36 is Positive, neither overbought nor oversold. The STOCH value of 37.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:ALC.
Alcidion Group Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | AU$18.37B | 77.46 | 72.67% | 0.39% | 22.87% | 130.30% | |
67 Neutral | AU$120.92M | 31.38 | 4.37% | ― | 36.43% | ― | |
55 Neutral | AU$65.80M | -6.57 | -23.86% | ― | -11.45% | -97.22% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$33.68M | -5.75 | -14.19% | ― | 0.03% | -5.85% | |
49 Neutral | AU$128.51M | -6.42 | -226.75% | ― | 29.37% | -10.38% | |
43 Neutral | AU$806.67M | -28.19 | -35.63% | ― | 123.08% | 5.34% |
* Healthcare Sector Average
AU:ALC
Alcidion Group Limited
0.09
-0.01
-13.00%
AU:ONE
Oneview Healthcare Chess Depository Interests repr 1
0.17
-0.07
-30.61%
AU:PME
Pro Medicus Limited
196.75
-120.05
-37.89%
AU:M7T
Mach7 Technologies
0.29
-0.07
-18.57%
AU:BMT
Beamtree Holdings Ltd
0.10
-0.16
-61.54%
AU:AYA
Artrya Limited
4.71
3.37
251.49%
Alcidion Group Limited Corporate Events
Alcidion Delivers Record Cashflow, Secures Major EPR Deals and Expands Patient Flow Footprint
Jul 22, 2026
Alcidion reported a record Q4 FY26 with positive operating cashflow of $7.7 million and quarterly cash receipts of $24.6 million, contributing to full-year operating cashflow of $6.8 million and unaudited revenue of about $51.6 million. The compan...
Alcidion targets Asian investors with Singapore and Hong Kong roadshow
Jun 28, 2026
Alcidion Group Limited is a healthcare technology provider focused on digital solutions that streamline clinical workflows, enhance interoperability and support real-time clinical decision-making for hospitals and healthcare organisations. Its cor...
Alcidion Reconfirms FY26 Outlook and Closes Telstra Health Kyra Acquisition
Jun 28, 2026
Alcidion has reaffirmed its full-year FY26 guidance, expecting revenue to exceed $50 million, EBITDA to surpass $5 million and operating cash flow to remain broadly in line with the prior year, underpinned by strong financial performance and long-...
Alcidion Issues New Shares for Services in Equity-Based Move
May 28, 2026
Alcidion Group Limited has issued 606,060 fully paid ordinary shares at nil consideration in lieu of cash for services rendered, as previously announced, and has confirmed that these shares were issued without a prospectus under the Corporations A...
Alcidion seeks ASX quotation for new share issuance
May 28, 2026
Alcidion Group Limited has applied for quotation on the ASX of 606,060 new fully paid ordinary shares. The new securities, issued on May 29, 2026, expand the company’s listed capital base and arise from previously announced transactions, sig...
Alcidion Plans Modest Share Placement to Support Growth
May 28, 2026
Alcidion Group Limited has notified the ASX of a proposed issue of up to 606,060 fully paid ordinary shares. The new securities are to be issued via a placement or similar structure, with the proposed issue date set for 29 May 2026, signalling a m...
Alcidion wins $35m, seven-year EPR deal with University Hospitals Sussex
May 24, 2026
Alcidion Group Limited has secured a seven-year contract with University Hospitals Sussex NHS Foundation Trust to deploy its modular Miya Precision platform as the Trust’s new electronic patient record system. The deal, which includes module...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.